Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL576462 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL523900 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL8207326 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL27902911 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL5626616 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL576463 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL4529849 | 1.00 | KMT2A (0.63) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL9987097 | 0.90 | KMT2A (0.53) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL14405525 | 0.89 | KMT2A (0.60) | KMT2AMAPK1BRD4GRM5HSD11B1 | |
| SCHEMBL20306298 | 0.87 | KMT2A (0.48) | KMT2AMAPK1BRD4HSD11B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| CN-115003673-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022121844-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114621219-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-2736886-B1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2736886-B1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| CN-103827090-B | Substituted quinolines and their use as pharmaceuticals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-6656952-B2 | As antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-0995744-B1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0995744-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | KMT2A 2719/4885MAPK1 3311/4885BRD4 883/4885 |
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | Q6ZSR9, MRPL21, ABCC1 | KMT2A 1525/4885MAPK1 3073/4885BRD4 165/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | KMT2A 1836/4885MAPK1 2867/4885BRD4 664/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPK1 935/4885BRD4 967/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | KMT2A 2715/4885MAPK1 3351/4885BRD4 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.